We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 8 of 12 for:    vpm1002

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00749034
Recruitment Status : Completed
First Posted : September 9, 2008
Last Update Posted : May 20, 2010
Information provided by:
Vakzine Projekt Management GmbH

Brief Summary:
Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against TB for residents in endemic areas and persons at risk in non-endemic areas. The new live vaccine VPM1002 should be at least as potent as the currently used BCG vaccine and should cause fewer side effects (Kaufmann, 2007; Grode et al., 2005). It is formulated as lyophilised bacteria to be resuspended before intradermal injection. First application of VPM1002 in human male volunteers will evaluate its safety, local and systemic tolerability as well as its immunogenicity. The study has a dose-escalating sequential design with comparison to commercially available BCG. 80 volunteers in Germany will randomly be allocated to 4 groups each with 20 volunteers stratified for their history of BCG-vaccination.

Condition or disease Intervention/treatment Phase
Tuberculosis Healthy Biological: VPM1002 Biological: BCG Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination
Study Start Date : September 2008
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Safety Vaccines

Arm Intervention/treatment
Experimental: 1
VPM1002 in three dosages
Biological: VPM1002
live vaccine

Active Comparator: 2
Biological: BCG
commercially available live vaccine BCG

Primary Outcome Measures :
  1. Safety: physical examination, vital signs, ECG, liver sonography, chest X-ray, laboratory safety parameters (including haematology, coagulation, clinical chemistry and urinalysis), tolerability, recording of concomitant medication and adverse events [ Time Frame: days -1, 1, 2, 3, 5, 11, 29, 57 and month 6 ]

Secondary Outcome Measures :
  1. Immunogenicity: LST for PPD with subsequent IFN-gamma specific ELISA on supernatants of PBMC [ Time Frame: baseline, days 29, 57, month 6 ]
  2. Immunogenicity: ELISPOT for the number of IFN-gamma secreting PBMC after stimulation with PPD [ Time Frame: baseline, days 29, 57, month 6 ]
  3. Immunogenicity: whole blood stimulated with PPD and measuring IFN-gamma in the plasma by ELISA [ Time Frame: baseline, days 29, 57, month 6 ]
  4. ICS for IFN-gamma, TNF-alpha and IL-2 in CD4+ and CD8+ lymphocytes upon stimulation with PPD [ Time Frame: baseline, days 29, 57 and month 6 ]
  5. Immunogenicity: ICS with other triple combinations of markers in CD4+ and CD8+ lymphocytes upon stimulation with PPD [ Time Frame: baseline, days 29, 57 and month 6 ]
  6. Immunogenicity: TB85B as recall antigen for ELISA, ELISPOT, WBA and ICS [ Time Frame: baseline, days 29, 57 and month 6 ]
  7. Immunogenicity: serum antibodies against PPD or AG85B [ Time Frame: baseline, days 29, 57 and month 6 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Male volunteers 18 to 55 years of age.
  2. Healthy (medical history, physical examination, vital signs, ECG and laboratory tests at screening).
  3. No signs of active or latent tuberculosis infection.
  4. BMI of 19 - 30 kg/m2.
  5. Subjects must be able and willing to comply with the study protocol, available and willing to complete all study measurements and have signed an Informed Consent form approved by the Ethics Committee.
  6. Intention not to travel to endemic regions for tuberculosis (such as Africa, Asia, former USSR) and reachable by phone during the whole study period (6 months).
  7. Negative test for HIV1 and HIV2, hepatitis B surface antigen and antibody to hepatitis C virus .
  8. No anamnestic evidence for a primary or secondary immunodeficiency.
  9. No skin eczema lesion at the intended injection site.
  10. No anamnestic predisposition for scarring badly or for keloid formation.
  11. No other vaccination during eight weeks before and during the follow-up period of the current study. If a vaccination is necessary during this period, the volunteer will be withdrawn from the study.
  12. No participation in another clinical trial within 3 months before study vaccination and the 6 months of the current study.
  13. Able and willing to abstain from physical exercise 24 hours before screening examination, and from 24 hours before admission until discharge from the clinic.
  14. No blood donation for non study-related purposes during the entire duration of the study.
  15. normal sonographic liver imaging

Exclusion Criteria:

For the group of volunteers who were vaccinated with a BCG vaccine:

• Tuberculin-PPD-in-vivo-test equal or more than 10 mm at baseline

For the group of naive volunteers:

• Tuberculin-PPD-in-vivo-Test equal or more than 1 mm at baseline

For all volunteers

  1. systemic disorders which could interfere with the interpretation of the study results or compromise the health of the volunteers.
  2. BCG-vaccination during 10 years before study vaccination.
  3. Acute fever or fever in the last 7 days before dosing.
  4. Any malignant condition.
  5. Concomitant treatment with medication that may affect immune function during 3 months before study vaccination and the 6 months of current study.
  6. Treatment with blood products or Immunoglobulins in the past 6 months up to end of study.
  7. Any clinically significant laboratory abnormalities on screened blood samples.
  8. A history of drug or alcohol abuse.
  9. History of anaphylaxis or severe allergic reactions.
  10. Positive test for drugs of abuse on urine testing at screening or admission.
  11. Known allergies to any component of the investigational or reference product or known history of severe skin reaction against the Tuberculin test.
  12. Professional or regular contact with life animals for food production.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00749034

Layout table for location information
Focus Clinical Drug Development GmbH
Neuss, Germany, 41460
Sponsors and Collaborators
Vakzine Projekt Management GmbH
Layout table for investigator information
Principal Investigator: Andreas Schrödter, MD FOCUS CDD GmbH
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. Hans-Heinrich Henneicke - v. Zepelin / CPM, Vakzine Projekt Management GmbH
ClinicalTrials.gov Identifier: NCT00749034    
Other Study ID Numbers: VPM1002-GE-1.01TB
First Posted: September 9, 2008    Key Record Dates
Last Update Posted: May 20, 2010
Last Verified: April 2010
Keywords provided by Vakzine Projekt Management GmbH:
Vaccination against tuberculosis
Safety and immunogenicity of VPM1002 in comparison with BCG
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses